Welcome to our dedicated page for Mindset Pharma news (Ticker: MSSTF), a resource for investors and traders seeking the latest updates and insights on Mindset Pharma stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mindset Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mindset Pharma's position in the market.
Mindset Pharma Inc. (OTCQB: MSSTF) announced that its lead psychedelic drug candidate, MSP-1014, exhibits superior efficacy and safety in pre-clinical tests compared to psilocybin. Using the mouse head twitch response assay, MSP-1014 showed over double the response of psilocybin without reducing locomotor activity or causing temperature changes. CEO James Lanthier highlighted MSP-1014's potential as a safer, scalable treatment for neuropsychiatric disorders. The company continues to develop a diverse pipeline of next-generation psychedelic medicines.
Mindset Pharma (OTCQB: MSSTF) announced a partnership with InterVivo Solutions to launch the Cooperative Psychedelics Evaluation Platform (COPE). This program aims to establish preclinical data benchmarks for psychedelic drugs like psilocybin and LSD. Preliminary data indicates a strong correlation between human clinical exposure and animal model efficacy, potentially enhancing drug development processes. Mindset's CEO expressed optimism about the insights gained, which are intended to address unmet needs in mental health treatments.
Mindset Pharma Inc. (CSE: MSET, OTCQB: MSSTF) announced the selection of MSP-1014 as its lead clinical candidate, based on superior safety and efficacy compared to psilocybin in preclinical studies. The compound is set to move into cGMP manufacturing and IND-enabling studies, marking a key milestone for the company. MSP-1014 aims to treat various mood disorders with potentially reduced side effects and lower clinical doses. Mindset continues to innovate in developing next-generation psychedelic medicines for unmet medical needs.